首页> 外文OA文献 >Efficacy of Surgery and Adjuvant Therapy in Older Patients With Colorectal Cancer A STROBE-compliant article
【2h】

Efficacy of Surgery and Adjuvant Therapy in Older Patients With Colorectal Cancer A STROBE-compliant article

机译:老年结直肠癌患者的外科手术和辅助治疗的疗效符合STROBE的文章

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study aimed to assess the efficacy of surgery and adjuvant therapy in older patients (age greater than= 70 years) with colorectal cancer (CRC). Older CRC patients are under-represented in available clinical trials, and therefore their outcomes after receiving surgery and adjuvant therapy are unclear. From two prospective Swedish databases, we assessed a cohort of 1021 patients who underwent curative surgery for stage I, II, or III primary CRC, with or without adjuvant chemotherapy/ radiotherapy. Of the patients with colon cancer (n = 467), 182 (39%) were aged less than70 years, 162 (35%) aged 70 to 80 years, and 123 (26%) were aged greater than= 80 years. Of rectal cancer patients (n = 554), 264 (48%) were aged less than70 years, 234 (42%) aged 70 to 80 years, and 56 (10%) aged greater than= 80 years. Older patients with either colon or rectal cancer had higher comorbidity than did younger patients. Older patients with colon cancer had equivalent postoperative morbidity and 30-day mortality to younger patients. Rectal cancer patients aged greater than= 80 years had a higher 30-day mortality than younger patients (odds ratio OR], 2.37; 95% confidence interval CI], 1.6-4.55; P = 0.03). For either colon or rectal cancer, adjuvant chemotherapy compromised the 5-year overall survival (OS) of older patients with stage II disease and had no effect on those with stage III disease. Receiving adjuvant chemotherapy was a poor factor of OS for older patients with either colon (HR 1.88, 95% CI: 1.20-4.35, P = 0.03) or rectal cancer (HR 1.72, 95% CI: 1.052.26, P = 0.004). Preoperative short-course radiotherapy improved both OS and local control for older patients with stage III rectal cancer and had no effect on those with stage II disease. Radiotherapy was a favorable factor for the OS of the older patients with rectal cancer (HR 0.42, 95% CI: 0.21-3.57, P = 0.01). In conclusion, Older CRC patients had equal safety of surgery as younger patients, except rectal cancer patients aged greater than= 80 years that had a higher mortality. Adjuvant 5FU-based chemotherapy did not benefit older CRC patient, while neoadjuvant radiotherapy improved the prognosis of older patients with stage III rectal cancer.
机译:本研究旨在评估大肠癌(CRC)老年患者(年龄大于70岁)的手术和辅助治疗效果。较老的CRC患者在可用的临床试验中代表性不足,因此尚不清楚他们接受手术和辅助治疗后的结局。我们从两个前瞻性的瑞典数据库中,评估了1021例接受I,II或III期原发性CRC治愈或不辅助化疗/放疗的患者。在结肠癌患者中(n = 467),年龄在70岁以下的有182名(39%),年龄在70至80岁的162名(35%),大于80岁的有123名(26%)。直肠癌患者(n = 554)中,年龄小于70岁的患者为264(48%),年龄70至80岁的患者为234(42%),年龄大于80岁的患者为56(10%)。结肠癌或直肠癌的老年患者合并症的发病率高于年轻患者。老年结肠癌患者的术后发病率和30天死亡率与年轻患者相同。年龄大于等于80岁的直肠癌患者比年轻患者的30天死亡率更高(几率OR)为2.37; 95%置信区间CI为1.6-4.55; P = 0.03。对于结肠癌或直肠癌,辅助化疗会损害患有II期疾病的老年患者的5年总生存期(OS),并且对患有III期疾病的患者没有影响。对于结肠癌(HR 1.88,95%CI:1.20-4.35,P = 0.03)或直肠癌(HR 1.72,95%CI:1.052.26,P = 0.004)的老年患者,接受辅助化疗是OS不良的一个因素。 。术前短程放疗改善了III期直肠癌老年患者的OS和局部控制,对II期疾病患者无影响。放射治疗是老年直肠癌患者OS的有利因素(HR 0.42,95%CI:0.21-3.57,P = 0.01)。总之,除年龄大于等于80岁的直肠癌患者死亡率较高外,老年CRC患者与年轻患者具有相同的手术安全性。辅助的基于5FU的化疗并没有使老年CRC患者受益,而新辅助放疗改善了老年III期直肠癌患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号